UA75896C2 - Pharmaceutical composition containing epinastine and pseudoephedrine, and method for treatment of allergic rhinitis - Google Patents
Pharmaceutical composition containing epinastine and pseudoephedrine, and method for treatment of allergic rhinitis Download PDFInfo
- Publication number
- UA75896C2 UA75896C2 UA2003054060A UA2003054060A UA75896C2 UA 75896 C2 UA75896 C2 UA 75896C2 UA 2003054060 A UA2003054060 A UA 2003054060A UA 2003054060 A UA2003054060 A UA 2003054060A UA 75896 C2 UA75896 C2 UA 75896C2
- Authority
- UA
- Ukraine
- Prior art keywords
- layer
- compositions
- pseudoephedrine
- coating
- tablet
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract description 19
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 title abstract description 10
- 229960003449 epinastine Drugs 0.000 title abstract description 9
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 title abstract description 8
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 title abstract description 7
- 229960003908 pseudoephedrine Drugs 0.000 title abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 title description 3
- 206010039085 Rhinitis allergic Diseases 0.000 title description 2
- 201000010105 allergic rhinitis Diseases 0.000 title description 2
- 239000000203 mixture Substances 0.000 abstract description 53
- 150000003839 salts Chemical class 0.000 abstract description 15
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 8
- 239000000739 antihistaminic agent Substances 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 239000003937 drug carrier Substances 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 208000026935 allergic disease Diseases 0.000 abstract description 2
- 230000001387 anti-histamine Effects 0.000 abstract description 2
- 239000000850 decongestant Substances 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 description 26
- 239000011248 coating agent Substances 0.000 description 25
- 238000004519 manufacturing process Methods 0.000 description 15
- 238000013270 controlled release Methods 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 239000008108 microcrystalline cellulose Substances 0.000 description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- CAVQBDOACNULDN-NRCOEFLKSA-N (1s,2s)-2-(methylamino)-1-phenylpropan-1-ol;sulfuric acid Chemical compound OS(O)(=O)=O.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 CAVQBDOACNULDN-NRCOEFLKSA-N 0.000 description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 229960004159 pseudoephedrine sulfate Drugs 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 230000000172 allergic effect Effects 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 230000000181 anti-adherent effect Effects 0.000 description 4
- 229940125715 antihistaminic agent Drugs 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000003973 paint Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 229940069328 povidone Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- -1 hydrochloric acid Chemical class 0.000 description 3
- 239000002966 varnish Substances 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- 241001274613 Corvus frugilegus Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical group [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- CEZCCHQBSQPRMU-UHFFFAOYSA-L chembl174821 Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-UHFFFAOYSA-L 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002388 eustachian tube Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 235000019691 monocalcium phosphate Nutrition 0.000 description 2
- 230000000510 mucolytic effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 241000755093 Gaidropsarus vulgaris Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- XKXPEVVVXXTWGR-UHFFFAOYSA-N [Na].[Na].[Na].C(=O)(O)C1(NN(C(=C1C1=CC=C(C=C1)S(=O)(=O)O)O)C1=CC=C(C=C1)S(=O)(=O)O)N=NC1=NNC=C1 Chemical compound [Na].[Na].[Na].C(=O)(O)C1(NN(C(=C1C1=CC=C(C=C1)S(=O)(=O)O)O)C1=CC=C(C=C1)S(=O)(=O)O)N=NC1=NNC=C1 XKXPEVVVXXTWGR-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 description 1
- 229960005174 ambroxol Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960003870 bromhexine Drugs 0.000 description 1
- OJGDCBLYJGHCIH-UHFFFAOYSA-N bromhexine Chemical compound C1CCCCC1N(C)CC1=CC(Br)=CC(Br)=C1N OJGDCBLYJGHCIH-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229920003064 carboxyethyl cellulose Polymers 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
- 239000004174 erythrosine Substances 0.000 description 1
- 229940011411 erythrosine Drugs 0.000 description 1
- 235000012732 erythrosine Nutrition 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000010855 food raising agent Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 235000013980 iron oxide Nutrition 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 238000009475 tablet pressing Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00121828 | 2000-10-06 | ||
| PCT/EP2001/011229 WO2002028373A1 (en) | 2000-10-06 | 2001-09-28 | New pharmaceutical compositions containing epinastine and pseudoephedrine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA75896C2 true UA75896C2 (en) | 2006-06-15 |
Family
ID=8170029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2003054060A UA75896C2 (en) | 2000-10-06 | 2001-09-28 | Pharmaceutical composition containing epinastine and pseudoephedrine, and method for treatment of allergic rhinitis |
Country Status (32)
| Country | Link |
|---|---|
| EP (1) | EP1326586B1 (zh) |
| JP (1) | JP2004521864A (zh) |
| KR (1) | KR20030036894A (zh) |
| CN (1) | CN1291715C (zh) |
| AR (2) | AR032479A1 (zh) |
| AT (1) | ATE424813T1 (zh) |
| AU (2) | AU2002212290B2 (zh) |
| BG (1) | BG107686A (zh) |
| BR (1) | BR0114339A (zh) |
| CA (1) | CA2423288C (zh) |
| CZ (1) | CZ2003945A3 (zh) |
| DE (1) | DE60137952D1 (zh) |
| EA (1) | EA007288B1 (zh) |
| EC (1) | ECSP034513A (zh) |
| EE (1) | EE200300138A (zh) |
| ES (1) | ES2323570T3 (zh) |
| HK (1) | HK1062196A1 (zh) |
| HR (1) | HRP20030259A2 (zh) |
| HU (1) | HUP0300970A3 (zh) |
| IL (1) | IL154884A0 (zh) |
| ME (1) | MEP39708A (zh) |
| MX (1) | MXPA03002900A (zh) |
| MY (1) | MY131159A (zh) |
| NO (1) | NO20031537L (zh) |
| NZ (1) | NZ525653A (zh) |
| PE (1) | PE20020324A1 (zh) |
| PL (1) | PL366123A1 (zh) |
| SK (1) | SK4052003A3 (zh) |
| UA (1) | UA75896C2 (zh) |
| WO (1) | WO2002028373A1 (zh) |
| YU (1) | YU24603A (zh) |
| ZA (1) | ZA200302079B (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0210534A (pt) * | 2001-06-20 | 2004-06-22 | Schering Corp | Anti-histaminas para o tratamento de congestão nasal e obstrução nasal |
| JP4549618B2 (ja) * | 2001-11-22 | 2010-09-22 | 第一三共ヘルスケア株式会社 | 鼻炎用組成物 |
| CA2494065A1 (en) * | 2002-08-02 | 2004-02-19 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulations comprising combinations of epinastine, pseudoephedrine and methylephedrine |
| JP5021155B2 (ja) * | 2003-08-01 | 2012-09-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | エピナスチンと１種以上のさらなる抗−ｈ１−ヒスタミン類との組合せを含む皮膚疾患治療用製薬組成物 |
| US20070196396A1 (en) * | 2004-02-11 | 2007-08-23 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0903151A1 (en) * | 1997-09-22 | 1999-03-24 | ASTA Medica Aktiengesellschaft | Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms |
| ATE331522T1 (de) * | 1997-12-23 | 2006-07-15 | Schering Corp | Zusammensetzung zur behandlung von atemwegs- und hauterkrankungen mit mindestens einem leukotrienantagonist und mindestens einem antihistaminikum |
| CN1329490A (zh) * | 1998-10-09 | 2002-01-02 | 先灵公司 | 用于治疗变应性疾病的组合物和方法 |
| US6613357B2 (en) * | 2000-01-13 | 2003-09-02 | Osmotica Corp. | Osmotic device containing pseudoephedrine and an H1 antagonist |
-
2001
- 2001-09-04 PE PE2001000883A patent/PE20020324A1/es not_active Application Discontinuation
- 2001-09-28 CN CNB018169376A patent/CN1291715C/zh not_active Expired - Lifetime
- 2001-09-28 HU HU0300970A patent/HUP0300970A3/hu unknown
- 2001-09-28 KR KR10-2003-7004846A patent/KR20030036894A/ko not_active Application Discontinuation
- 2001-09-28 AU AU2002212290A patent/AU2002212290B2/en not_active Ceased
- 2001-09-28 IL IL15488401A patent/IL154884A0/xx unknown
- 2001-09-28 ME MEP-397/08A patent/MEP39708A/xx unknown
- 2001-09-28 EE EEP200300138A patent/EE200300138A/xx unknown
- 2001-09-28 JP JP2002531999A patent/JP2004521864A/ja active Pending
- 2001-09-28 SK SK405-2003A patent/SK4052003A3/sk unknown
- 2001-09-28 CA CA002423288A patent/CA2423288C/en not_active Expired - Lifetime
- 2001-09-28 EP EP01980449A patent/EP1326586B1/en not_active Expired - Lifetime
- 2001-09-28 MX MXPA03002900A patent/MXPA03002900A/es active IP Right Grant
- 2001-09-28 AT AT01980449T patent/ATE424813T1/de active
- 2001-09-28 PL PL01366123A patent/PL366123A1/xx unknown
- 2001-09-28 CZ CZ2003945A patent/CZ2003945A3/cs unknown
- 2001-09-28 NZ NZ525653A patent/NZ525653A/en unknown
- 2001-09-28 WO PCT/EP2001/011229 patent/WO2002028373A1/en active Application Filing
- 2001-09-28 EA EA200300430A patent/EA007288B1/ru not_active IP Right Cessation
- 2001-09-28 BR BR0114339-5A patent/BR0114339A/pt not_active Application Discontinuation
- 2001-09-28 ES ES01980449T patent/ES2323570T3/es not_active Expired - Lifetime
- 2001-09-28 UA UA2003054060A patent/UA75896C2/uk unknown
- 2001-09-28 AU AU1229002A patent/AU1229002A/xx active Pending
- 2001-09-28 DE DE60137952T patent/DE60137952D1/de not_active Expired - Lifetime
- 2001-09-28 YU YU24603A patent/YU24603A/sh unknown
- 2001-10-04 MY MYPI20014635A patent/MY131159A/en unknown
- 2001-10-05 AR ARP010104692A patent/AR032479A1/es not_active Application Discontinuation
-
2003
- 2003-03-13 EC EC2003004513A patent/ECSP034513A/es unknown
- 2003-03-14 ZA ZA200302079A patent/ZA200302079B/en unknown
- 2003-03-28 BG BG107686A patent/BG107686A/bg unknown
- 2003-04-04 NO NO20031537A patent/NO20031537L/no not_active Application Discontinuation
- 2003-04-04 HR HR20030259A patent/HRP20030259A2/hr not_active Application Discontinuation
-
2004
- 2004-06-09 HK HK04104141A patent/HK1062196A1/xx not_active IP Right Cessation
-
2012
- 2012-07-19 AR ARP120102612A patent/AR087240A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021202009B2 (en) | Pharmaceutical formulations comprising tenofovir and emtricitabine | |
| RU2616516C2 (ru) | Фармацевтическая композиция, содержащая олмесартана медоксомил и розувастатин или его соль | |
| TWI314868B (en) | Pharmaceutical preparation containining 5-methyl-1-phenyl-2-(1h)-pyridone as an active ingredient | |
| AU2003229705C1 (en) | High drug load tablet | |
| US10842759B2 (en) | Pharmaceutical compositions for N-propargylamine derivative | |
| EP2540318B1 (en) | Sustained-release solid preparation for oral use | |
| JPS5883618A (ja) | ニトロフラントイン投与剤 | |
| UA75896C2 (en) | Pharmaceutical composition containing epinastine and pseudoephedrine, and method for treatment of allergic rhinitis | |
| US8835495B2 (en) | Pharmaceutical composition comprising cyclobenzaprine and aceclofenac in association | |
| EP4048276A1 (en) | Solid pharmaceutical formulations comprising ticagrelor | |
| US20230225977A1 (en) | Formulation comprising daprodustat | |
| MXPA06003479A (es) | Una composicion farmaceutica de liberacion prolongada y un proceso para su preparacion. | |
| JP2003300872A (ja) | 被覆固形催眠製剤 | |
| WO2018028841A1 (en) | Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz | |
| WO2017029225A1 (en) | Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz | |
| RU2593570C1 (ru) | Противовирусное и иммуностимулирующее лекарственное средство | |
| Shah et al. | Formulation and Development of Fast Disintegrating Tablets Using Ranitidine HCL as a Model Drug | |
| TWI810656B (zh) | 二氟甲基鳥氨酸及舒林酸（ｓｕｌｉｎｄａｃ），固定劑量組合調配物 | |
| Patil | A Review: A new trend in drug delivery Oro-dispersible tablets | |
| WO2021117697A1 (ja) | 固形製剤 | |
| RU2773029C2 (ru) | Галеновые композиции органических соединений | |
| PATEL | Development and optimization of immediate release tablet of febuxostat in gout treatment | |
| AU2007201830C1 (en) | High drug load tablet | |
| Sahu et al. | Formulation and evaluation of Tolperisone hydrochloride sustained release tablet | |
| Lokesha | Design and In-Vitro Evaluation of Fast Disintegrating Tablets of an Antihypertensive Drug |